TY - JOUR
TI - Haemostatic profile of riboflavin-treated apheresis platelet concentrates.
AU - Petrou, Eleni
AU - Nikolopoulos, Georgios K.
AU - Kriebardis, Anastasios G.
AU - Pantavou, Katerina
AU - Loukopoulou, Electra
AU - Tsantes, Andreas G.
AU - Georgatzakou, Hara T.
AU - Maratou, Eirini
AU - Rapti, Evdoxia
AU - Mellou, Sofia
AU - Kokoris, Styliani
AU - Gialeraki, Argyri
AU - Tsantes, Argirios E.
JO - Blood transfusion = Trasfusione del sangue
PY - 2021
VL - null
TODO - null
SP - null
PB - 
SN - null
TODO - 10.2450/2021.0089-21
TODO - null
TODO - BACKGROUND: The haemostatic activity of platelet concentrates (PCs) treated with pathogen reduction technology (PRT) remains a subject of debate. Our aim was to  investigate the effect of Mirasol PRT on the haemostatic properties of PCs stored in  plasma. MATERIAL AND METHODS: Untreated and Mirasol-treated platelets stored in  plasma and derived from ten split double-dose apheresis PCs were evaluated in vitro  on days 1, 3 and 5 post collection for functionality, microparticle procoagulation  activity (MPA), endogenous thrombin potential (ETP), and haemostatic profile using  rotational thromboelastometry (ROTEM). RESULTS: P-selectin expression was  significantly higher in Mirasol-treated platelets compared with untreated  counterparts on days 3 and 5 (p=0.003 and p=0.002, respectively). Clot strength, as  shown by EXTEM maximum clot firmness (MCF), was significantly lower in the  Mirasol-treated platelets at all time points (days 1, 3, 5) than in untreated  platelets (p=0.009, p<0.001, p<0.001, respectively). There was a considerable  increase in MPA over time (p<0.001) and this was significantly higher in the  Mirasol-treated platelets on day 5 (p=0.015). A notable acceleration of decrease in  ETP values was observed for Mirasol-treated PCs over time (p<0.001), with  significant differences between PRT-treated and untreated PCs on days 3 and 5  (p=0.038 and p=0.019, respectively). Clot strength attenuation was significantly  associated with pH reduction (p<0.001, Spearman’s rho: 0.84), increased  microparticle procoagulant activity (p<0.001, Spearman’s rho: -0.75), and with  decreased ETP (p<0.032, Spearman’s rho: 0.41). DISCUSSION: Increased platelet  activation induced by PRT treatment leads to a decrease in in vitro haemostatic  capacity as seen by reduced clot strength and thrombin generation capacity over  time. The clinical relevance of this needs to be investigated.
ER -